All In Biotech

Drug Trial Radar · NCT01928433

Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis

A Multi-Dose, Double-Blind, Double-Dummy, Active- Control, Randomized Clinical (Phase II) Study of Two Dosing Regimens of Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Requiring Hospitalisation.

Last checked: Nov 19, 2026Latest source record: Jun 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 225 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

225

Actual

Start

Dec 2012

Primary completion

Jun 2014

Study completion Oct 2015

Sponsor

Lead sponsor
MerLion Pharmaceuticals GmbHIndustry
Sponsor type
Industry
First posted
Aug 26, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the microbiological and clinical outcome of treatment with finafloxacin for 5 days versus finafloxacin for 10 days versus ciprofloxacin for 10 days as a reference comparator. Finafloxacin shows increased activity in an acidic environment which is associated with indications such as uUTI and cUTI. Given the acidic pH of urine and concentration of finafloxacin excreted via the urinary tract in humans it should be proven if the finafloxacin treatments offer significant advantages over the currently available treatments for UTI.

Conditions

  • Urinary Tract Infections
  • Acute Pyelonephritis

Interventions

  • Finafloxacin 800 mg i.v. once dailyDrug

    Infused over 60 mins \[i.v. pump\]) for at least 3 days.

  • Finafloxacin placebo i.v. once dailyDrug

    Infused over 60 mins \[i.v. pump\]) for at least 3 days.

  • Finafloxacin 800 mg tablets once dailyDrug

    Administered as four 200 mg tablets

  • Finafloxacin placebo tablets once dailyDrug

    Administered as four tablets

  • Ciprofloxacin 400 mg i.v. twice dailyDrug

    Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days

  • Ciprofloxacin placebo i.v. twice dailyDrug

    Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days

  • Ciprofloxacin 500 mg oral twice dailyDrug

    Administered as two 250 mg capsules.

  • Ciprofloxacin placebo oral twice dailyDrug

    Administered as two capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Clinical and Microbiological ResponseTime frame: Day 17

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Universitätsklinikum Giessen, Klinik für Urologie, Kinderurologie und Andrologie

    Giessen, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.